Xtl Biopharmaceuticals (XTLB) Share-based Compensation (2009 - 2013)

Xtl Biopharmaceuticals (XTLB) posted quarterly Share-based Compensation of $13000.0 for Q3 2013, down 87.85% on a QoQ basis from $107000.0 in Q1 2010.

Xtl Biopharmaceuticals (XTLB) Share-based Compensation (2009 - 2013) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported Share-based Compensation for 3 consecutive years, with $13000.0 the latest figure, recorded in Q3 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Share-based Compensation (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 6.39 Mn
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 305,000.00
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 9.26 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 166.40 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 257.40 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - 87.30 Mn
10 Xtl Biopharmaceuticals 2.58 Bn 2.58 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2013 13,000.00
Sep 30, 2013 13,000.00
Mar 31, 2010 107,000.00
Mar 31, 2010 107,000.00
Mar 31, 2009 -2.54 Mn
Mar 31, 2009 -2.54 Mn